Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
RAS mutations are common in myeloid malignancies; however, it is not known whether oncogenic RAS can initiate leukemia. We show that expressing mutant K-Ras(G12D) protein from the endogenous murine locus rapidly induces a fatal myeloproliferative disorder with 100% penetrance characterized by tissue infiltration, hypersensitivity to growth factors, and hyperproliferation. Hematopoietic cells from diseased mice demonstrated increased levels of Ras-GTP, but effector kinases were not constitutively phosphorylated and responded normally to growth factors. Oncogenic RAS is sufficient to initiate myeloid leukemogenesis in mice, and this provides an in vivo system for biologic and preclinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Expression of the most common KRAS mutation (G12D) in mouse hematopoietic cells causes a fatal myeloproliferative neoplasm (MPN).6,7”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
The GTPase superfamily: a conserved switch for diverse cell functions
Bourne, H. R., Sanders, D. A., & McCormick, F. (1990) · Nature · doi:10.1038/348125a0 · Cited by 2,333
Proteins regulating Ras and its relatives
Boguski, M. S., & McCormick, F. (1993) · Nature · doi:10.1038/366643a0 · Cited by 1,901
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationThiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Research works printed but not linked: 6
- Bos, J. L. (1989) Cancer Res. 49, 4682-4689.
- Padua, R. A., Carter, G., Hughes, D., Gow, J., Farr, C., Oscier, D., McCormick, F. & Jacobs, A. (1988) Leukemia 2, 503-510.
- Bashey, A., Gill, R., Levi, S., Farr, C. J., Clutterbuck, R., Millar, J. L., Pragnell, I. B. & Marshall, C. J. (1992) Blood 79, 981-989. · doi:10.1182/blood.v79.4.981.bloodjournal794981
- Dunbar, C. E., Crosier, P. S. & Nienhuis, A. W. (1991) Oncogene Res. 6, 39-51.
- Hawley, R. G., Lieu, F. H., Fong, A. Z. & Hawley, T. S. (1994) Gene Ther. 1, 136-138.
- Donovan, S., Shannon, K. M. & Bollag, G. (2002) BBA Rev. Cancer. 1602, 23-45.
Cited by
Items 101–200 of 308
Pleiotrophin mediates hematopoietic regeneration via activation of RAS
Himburg, H. A., Yan, X., Doan, P. L., Quarmyne, M., Micewicz, E., McBride, W., Chao, N. J., Slamon, D. J., & Chute, J. P. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76838 · Cited by 58
Kratz, C. P., Schubbert, S., Bollag, G. E., Niemeyer, C. M., Shannon, K., & Zenker, M. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3128 · Cited by 63
Self-citationMouse Models of Human Non-Small-Cell Lung Cancer: Raising the Bar
KIM, C. F. B., JACKSON, E. L., KIRSCH, D. G., GRIMM, J., SHAW, A. T., LANE, K., KISSIL, J., OLIVE, K. P., SWEET-CORDERO, A., WEISSLEDER, R., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.037 · Cited by 58
Self-citationDvorak, C. C., & Loh, M. L. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00025 · Cited by 59
Gough, D. J., Marié, I. J., Lobry, C., Aifantis, I., & Levy, D. E. (2014) · Blood · doi:10.1182/blood-2013-02-484196 · Cited by 57
“Poly(I:C)-injected Mx-1–Cre:K-RasLSL:STAT3-LoxP/1 mice (referred to as Mx:K-Ras:F/1) are expected to develop MPNs with shared characteristics of JMML, including expansion of myeloid progenitors in the marrow and periphery, splenomegaly, and extramedullary hematopoiesis.(22,32) Induction of Mx-Cre effectively deleted t…”
BackgroundHematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
Gritsman, K., Yuzugullu, H., Von, T., Yan, H., Clayton, L., Fritsch, C., Maira, S.-M., Hollingworth, G., Choi, C., Khandan, T., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69927 · Cited by 55
“It has been previously demonstrated that induction of oncogenic KRAS in HSCs using the KMX system results in a rapidly lethal myeloproliferative neoplasm (MPN) in mice, resembling human JMML (38, 39).”
InfluentialAn unexpected new role of mutant Ras: perturbation of human embryonic development
Kratz, C. P., Niemeyer, C. M., & Zenker, M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0135-4 · Cited by 58
“In a murine model, somatic activation of K-Ras in hematopoietic cells initiates a rapidly fatal MPD modeling JMML [20, 21].”
BackgroundRole of cyclic AMP response element binding protein in human leukemias
Shankar, D. B., Cheng, J. C., & Sakamoto, K. M. (2005) · Cancer · doi:10.1002/cncr.21401 · Cited by 63
Non-Redundancy within the RAS Oncogene Family: Insights into Mutational Disparities in Cancer
Lau, K. S., & Haigis, K. M. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0143-7 · Cited by 63
“Moreover, endogenous activation of RAS in vivo, in hematopoetic and epithelial tissues, results in significantly attenuated signaling compared to over-expression of RAS in vitro (Braun et al., 2004; Guerra et al., 2003; Haigis et al., 2008; Tuveson et al., 2004).”
Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia
Koike, K., & Matsuda, K. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07104.x · Cited by 55
Ras signaling regulates osteoprogenitor cell proliferation and bone formation
Papaioannou, G., Mirzamohammadi, F., & Kobayashi, T. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.314 · Cited by 55
Chang, Y., You, X., Kong, G., Ranheim, E. A., Wang, J., Du, J., Liu, Y., Zhou, Y., Ryu, M.-J., & Zhang, J. (2015) · Leukemia · doi:10.1038/leu.2015.85 · Cited by 55
Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm
Kong, G., Wunderlich, M., Yang, D. T., Ranheim, E. A., Young, K. H., Wang, J., Chang, Y., Du, J., Liu, Y., Tey, S.-R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74182 · Cited by 52
“We and other laboratories previously developed 3 genetically engineered mouse models that express 1 or 2 copies of constitutively active Nras G12D or 1 copy of Kras G12D in the hematopoietic compartment ( Nras G12D/+ , Nras G12D/G12D , or Kras G12D/+ , respectively) (4, 7–13).”
Strategies to Achieve Conditional Gene Mutation in Mice
Gierut, J. J., Jacks, T., & Haigis, K. M. (2014) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069807 · Cited by 62
“In the presence of Cre, the STOP element is removed and oncogenic K-ras is expressed only in cells where the recombinase is expressed (Tuveson et al. 2004).”
InfluentialSelf-citationLiu, W., Yu, W.-M., Zhang, J., Chan, R. J., Loh, M. L., Zhang, Z., Bunting, K. D., & Qu, C.-K. (2016) · Leukemia · doi:10.1038/leu.2016.326 · Cited by 51
Wittsten, A. H., Pilheden, M., Sturesson, H., Hansson, J., Walsh, M. P., Song, G., Kazi, J. U., Liu, J., Ramakrishan, R., García-Ruiz, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04180-1 · Cited by 55
Zhang, X., Podsypanina, K., Huang, S., Mohsin, S. K., Chamness, G. C., Hatsell, S. J., Cowin, P., Schiff, R., & Li, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208597 · Cited by 57
“Similar lack of activation of these two Ras effectors has been reported in tumorigenesis of hematopoietic cells, induced by expressing mutated K-Ras from its endogenous promoter in mice (Braun et al., 2004).”
BackgroundIllmer, T., Thiede, C., Fredersdorf, A., Stadler, S., Neubauer, A., Ehninger, G., & Schaich, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2232 · Cited by 51
“It could be shown that these mutations account for phenotypic changes in transformed hematopoietic cells like hyperproliferation, hypersensitivity to growth factor stimulation, and IL-3– independent colony-forming unit activity (10, 11).”
BackgroundAbnormal hematopoiesis in Gab2 mutant mice
Zhang, Y., Diaz-Flores, E., Li, G., Wang, Z., Kang, Z., Haviernikova, E., Rowe, S., Qu, C.-K., Tse, W., Shannon, K. M., et al. (2007) · Blood · doi:10.1182/blood-2006-11-060707 · Cited by 49
Self-citationTargeting oncogenic Ras: Figure 1.
Díaz-Flores, E., & Shannon, K. (2007) · Genes & Development · doi:10.1101/gad.1587907 · Cited by 53
“…despite the apparent ability of normal cells to moderate the downstream consequences of hyperactive Ras, these mice are strongly predisposed to the development of fatal pancreatic, lung, and hematologic cancers (Guerra et al. 2003; Hingorani et al. 2003; Braun et al. 2004; Tuveson et al. 2004).”
BackgroundSelf-citationThe role of PKC and PDK1 in monocyte lineage specification by Ras
Pearn, L., Fisher, J., Burnett, A. K., & Darley, R. L. (2007) · Blood · doi:10.1182/blood-2006-09-047217 · Cited by 48
Khandanpour, C., Krongold, J., Schütte, J., Bouwman, F. C. M., Vaßen, L., Gaudreau, M., Chen, R., Calero‐Nieto, F. J., Diamanti, E., Hannah, R., et al. (2012) · Blood · doi:10.1182/blood-2011-02-334722 · Cited by 53
A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation
Bentley, C., Jurinka, S. S., Kljavin, N. M., Vartanian, S., Ramani, S. R., Gonzalez, L. C., Yu, K., Modrusan, Z., Du, P., Bourgon, R., et al. (2013) · Biochemical Journal · doi:10.1042/bj20121578 · Cited by 44
Robertson, A. L., Avagyan, S., Gansner, J. M., & Zon, L. I. (2016) · FEBS Letters · doi:10.1002/1873-3468.12415 · Cited by 45
Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
Gupta, A., Meena, J. P., Chopra, A., Tanwar, P., & Seth, R. K. (2021) · PubMed · Cited by 44
Deregulated Notch and Wnt signaling activates early-stage myeloid regeneration pathways in leukemia
Kang, Y.-A., Pietras, E. M., & Passegue, E. A. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190787 · Cited by 46
“Bones from Mx1-CRE::KrasLSL-G12D mice (Braun et al., 2004) were provided by Dr.”
BackgroundMethodCooperative loss of RAS feedback regulation drives myeloid leukemogenesis
Zhao, Z., Chen, C.-C., Rillahan, C. D., Shen, R., Kitzing, T., McNerney, M. E., Diaz-Flores, E., Zuber, J., Shannon, K., Le Beau, M. M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3251 · Cited by 43
“SNP array based copy number analyses of 35 samples are from published results 9 , and data analysis and expression level estimates were performed as described 9 .”
Self-citationFrequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia
Zebisch, A., Wölfler, A., Fried, I., Wolf, O., Lind, K., Bodner, C., Haller, M., Drasche, A., Pirkebner, D., Matallanas, D., et al. (2012) · Leukemia · doi:10.1038/leu.2012.61 · Cited by 45
“42, 43 Additional genetic alterations like inactivation of NF1 44 or expression of the PML-RARα fusion gene 45 were necessary to enable transition to AML.”
Wen, Z. H., Rajagopalan, A., Flietner, E. D., Yun, G., Chesi, M., Furumo, Q., Burns, R. T., Papadas, A., Ranheim, E. A., Pagenkopf, A. C., et al. (2020) · Blood · doi:10.1182/blood.2020007156 · Cited by 50
Kim, W.-I., Matise, I., Diers, M. D., & Largaespada, D. A. (2008) · Blood · doi:10.1182/blood-2008-01-132316 · Cited by 42
Zhang, L., Singh, R. R., Patel, K. P., Stingo, F. C., Routbort, M. J., You, M. J., Miranda, R. N., Garcia‐Manero, G., Kantarjian, H. M., Medeiros, L. J., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23652 · Cited by 42
Aydin, E., Hallner, A., Wiktorin, H. G., Staffas, A., Hellstrand, K., & Martner, A. (2018) · Oncogene · doi:10.1038/s41388-018-0528-1 · Cited by 42
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo
Braun, B. S., Archard, J. A., Ziffle, J. V., Tuveson, D. A., Jacks, T., & Shannon, K. (2006) · Blood · doi:10.1182/blood-2006-01-013490 · Cited by 41
Self-citationMouse models for BRAF-induced cancers
Pritchard, C. A., Carragher, L., Aldridge, V., Giblett, S. M., Jin, H., Foster, C., Andreadi, C., & Kamata, T. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351329 · Cited by 48
Myeloproliferative Neoplasm Animal Models
Mullally, A., Lane, S. W., Brumme, K., & Ebert, B. L. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.07.007 · Cited by 37
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras
Akutagawa, J., Huang, T. Q., Epstein, I., Chang, T., Quirindongo-Crespo, M., Cottonham, C. L., Dail, M., Slusher, B. S., Friedman, L. S., Sampath, D., et al. (2016) · Leukemia · doi:10.1038/leu.2016.14 · Cited by 35
Self-citationJuvenile myelomonocytic leukemia
Niemeyer, C. M., & Kratz, C. P. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0013-y · Cited by 38
“liferative disorder [15].”
JAKing up hematopoietic proliferation
Shannon, K., & Etten, R. A. V. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.002 · Cited by 38
Self-citationPrognostic impact of RAS mutations in patients with myelodysplastic syndrome
Al‐Kali, A., Quintás‐Cardama, A., Luthra, R., Bueso-Ramos, C., Pierce, S. A., Kadia, T. M., Borthakur, G. M., Estrov, Z. E., Jabbour, E. J., Faderl, S. H., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23410 · Cited by 37
Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
Baum, K. J., & Ren, R. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-5 · Cited by 37
“It has been shown that both oncogenic Ras and STAT5 can induce myeloproliferative disease [32-34], yet adult hematopoiesis appears normal in STAT5A/B-deficient mice [35].”
BackgroundWild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice
Staffas, A., Karlsson, C., Persson, M., Palmqvist, L., & Bergö, M. O. (2014) · Leukemia · doi:10.1038/leu.2014.315 · Cited by 36
Acute Myeloid Leukemia With t(9;11)(p21–22;q23)
Chandra, P., Luthra, R., Zuo, Z., Yao, H., Ravandi, F., Reddy, N., Garcia‐Manero, G., Kantarjian, H. M., & Jones, D. M. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpgii1tt4nyogi · Cited by 36
“Breast carcinoma 18 (62) 17* Doxorubicin (14); epirubicin (3) 25 (10-147) Sarcoma 4 (14) 4 Doxorubicin (3); irinotecan (1) 21 (12-38) Large B-cell lymphoma 3 (10) 2* Doxorubicin (2) 26 (24-26) Hodgkin lymphoma 2 (7) 2 Doxorubicin (2) 24 Testicular carcinoma 1 (3) 1 Etoposide 72 Prostate carcinoma 1 (3) 0 — 24”
Campbell, T., Basu, S., Hangoc, G., Tao, W., & Broxmeyer, H. E. (2009) · Blood · doi:10.1182/blood-2008-12-195214 · Cited by 36
Zhang, J., & Lodish, H. F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507446102 · Cited by 34
Archambeault, S., Flores, N. J., Yoshimi, A., Kratz, C. P., Reising, M., Fischer, A., Noellke, P., Locatelli, F., Sedláček, P., Flotho, C., et al. (2007) · Blood · doi:10.1182/blood-2007-06-093302 · Cited by 33
Germeshausen, M., Schulze, H., Kratz, C. P., Wilkens, L., Repp, R., Shannon, K., Welte, K., & Ballmaier, M. (2005) · Leukemia · doi:10.1038/sj.leu.2403663 · Cited by 32
Self-citationMeyer, M., Rübsamen, D., Slany, R. K., Illmer, T., Stabla, K., Roth, P., Stiewe, T., Eilers, M., & Neubauer, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007768 · Cited by 32
“Supporting this notion, oncogenic RAS alone induces a myeloproliferative state in murine models [8–12] and in cooperation with nuclear oncogenes such as PML-RARa induces acute leukemia [13].”
BackgroundYang, Z., Kondo, T., Voorhorst, C. S., Nabinger, S. C., Ndong, L., Yin, F., Chan, E. M., Yu, M., Würstlin, O., Kratz, C. P., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01330-08 · Cited by 33
“Consistent with the findings of other models of JMML (8, 12, 38, 45), we observed skewed monocytic differentiation of mutant Shp2-expressing hematopoietic progenitors in multiple assay systems.”
ResultJamalpour, M., Li, X., Gustafsson, K. U., Tyner, J. W., & Welsh, M. (2018) · Tumor Biology · doi:10.1177/1010428318771472 · Cited by 31
“The Kras2/Mx1-Cre (KM) mouse model has been used for triggering the expression of an oncogenic Kras in the bone marrow allowing the mice to develop T-cell leukemia and/or T-cell thymic lymphoma.(31,32) A combination of this oncogene with Shb deletion was used in order to investigate the effects of Shb deficiency on Kr…”
MethodInterplay between K-RAS and miRNAs
Shui, B., Rocca, G. L., Ventura, A., & Haigis, K. M. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.002 · Cited by 33
Li, C.-Y., Zhan, Y.-Q., Li, W., Cw, X., Xu, W.-X., Yu, D.-H., Peng, R.-Y., Cui, Y.-F., Yang, X., Hou, N., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404901 · Cited by 31
Stieglitz, E., Lee, A. G., Angus, S. P., Davis, C. M., Barkauskas, D. A., Hall, D. C., Kogan, S. C., Meyer, J., Rhodes, S. D., Tasian, S. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1376 · Cited by 30
Self-citationDefective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
Shieh, A., Ward, A. F., Donlan, K. L., Harding-Theobald, E. R., Xu, J., Mullighan, C. G., Zhang, C., Chen, S.-C., Su, X., Downing, J. R., et al. (2013) · Blood · doi:10.1182/blood-2012-05-432252 · Cited by 28
Self-citationMicro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
Berg, J. L., Perfler, B., Hatzl, S., Mayer, M.-C., Wurm, S., Uhl, B., Reinisch, A., Klymiuk, I., Tierling, S., Pregartner, G., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-020-00979-2 · Cited by 29
“Interestingly, Tatsumi and co-workers reported that mice with a complete deletion of miR-125a developed a less severe MPD phenotype than animals with a heterozygous deletion; the latter showing a decreased but still measurable miR-125a expression.”
MethodInfluentialRepressible transgenic model of NRAS oncogene–driven mast cell disease in the mouse
Wiesner, S. M., Jones, J. M., Hasz, D. E., & Largaespada, D. A. (2005) · Blood · doi:10.1182/blood-2004-08-3306 · Cited by 31
Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice
Cutts, B. A., Sjogren, A.-K. M., Andersson, K., Wahlstrom, A. M., Karlsson, C., Swolin, B., & Bergö, M. O. (2009) · Blood · doi:10.1182/blood-2009-02-205146 · Cited by 28
Fátrai, S., van Gosliga, D., Han, L., Daenen, S. M. G. J., Vellenga, E., & Schuringa, J. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.201848 · Cited by 28
Drosten, M., Simón-Carrasco, L., Hernández-Porras, I., Lechuga, C. G., Blasco, M. T., Jacob, H. K. C., Fabbiano, S., Potenza, N., Bustelo, X. R., Guerra, C. E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2925 · Cited by 30
“Barbacid), Castilla-Le on Autonomous Government (CSI101U13, BIO/SA01/15), the Spanish Ministry of Economy and Competitiveness (SAF2012-31371, RD12/0036/0002), Worldwide Cancer Research (14-1248), the Sol orzano Foundation, and the Ram on Areces Foundation (X.”
BackgroundConstitutive MAP Kinase Activation in Hematopoietic Stem Cells Induces a Myeloproliferative Disorder
Chung, E., Hsu, C.-L., & Kondo, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028350 · Cited by 27
“Lastly, the mixed MDS/MPN category, which was added in 2001, was specifically created to accommodate diseases such as juvenile myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML) [6].”
BackgroundResultInfluentialHirakawa, H., Suzue, K., Takita, A., Awazu, C., Kurushima, J., & Tomita, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-72412-w · Cited by 28
Physiological Analysis of Oncogenic K‐Ras
Pérez-Mancera, P. A., & Tuveson, D. A. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)07053-9 · Cited by 28
Self-citationChronic myelomonocytic leukemia: Forefront of the field in 2015
Benton, C. B., Nazha, A., Pemmaraju, N., & Garcia‐Manero, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.03.002 · Cited by 32
“A number of mouse models that overexpress Nras or Kras in the hematopoietic compartment have been shown to develop CMML-like disease [87-89].”
BackgroundElucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis
Grigsby, S. M., Friedman, A. D., Chase, J., Waas, B., Ropa, J. P., Serio, J., Shen, C., Muntean, A. G., Maillard, I. P., & Nikolovska‐Coleska, Z. (2021) · Cancers · doi:10.3390/cancers13040642 · Cited by 26
“The Mx1-Cre transgene encodes a Cre recombinase that yields robust excision of floxed genes upon poly(I:C) injection in vivo, especially within the hematopoietic system [50,51].”
BackgroundYoshimi, A., Kojima, S., & Hirano, N. (2009) · Pediatric Drugs · doi:10.2165/11316200-000000000-00000 · Cited by 26
“Recent mouse models of NF1-/-, KRASG12D andPTPN11D61G suggest that the deregulation of the RAS signaling pathway can initiate myeloproliferative diseases.([42-46]) However, it is not clear whether a mutation of only one of the PTPN11, RAS, or NF1 genes is sufficient to cause the development of JMML in humans.”
Wong, J. C. Y., Zhang, Y., Lieuw, K. H., Tran, M. T., Forgó, E., Weinfurtner, K. M., Alzamora, P., Kogan, S. C., Akagi, K., Wolff, L., et al. (2010) · Blood · doi:10.1182/blood-2009-07-232504 · Cited by 26
Self-citationelhefni (2011) · OncoTargets and Therapy · doi:10.2147/ott.s12602 · Cited by 26
“In most of these studies, the type of postremission treatment was not taken in account in the analysis of clinical outcome.(21,22) However, when we considered the K-RAS status and consolidation therapy, statistical analysis revealed that the Time (months) 0.”
Zhang, J., Liu, Y., Beard, C., Tuveson, D. A., Jaenisch, R., Jacks, T., & Lodish, H. F. (2007) · Blood · doi:10.1182/blood-2006-09-047050 · Cited by 26
Self-citationMechanisms of aneuploidy induction by RAS and RAF oncogenes.
Kamata, T., & Pritchard, C. A. (2011) · Europe PMC (PubMed Central) · Cited by 31
Juvenile myelomonocytic leukemia
Kratz, C. P., & Niemeyer, C. M. (2005) · Hematology · doi:10.1080/10245330512331390078 · Cited by 25
A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies
Maertens, O., McCurrach, M. E., Braun, B. S., Raedt, T. D., Epstein, I., Huang, T. Q., Lauchle, J., Lee, H.-R., Wu, J., Cripe, T. P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1789 · Cited by 25
“Because mutations in NF1 or KRAS also occur in sporadic myeloid diseases, Cre-lox–based models that incorporate these alterations have been developed (9, 10).”
InfluentialSelf-citationKrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice
Wong, J. C. Y., Pérez-Mancera, P. A., Huang, T. Q., Kim, J., Grego‐Bessa, J., Alzamora, M. D. P., Kogan, S. C., Sharir, A., Keefe, S. H., Morales, C. E., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140495 · Cited by 24
“Table 1 compares selected findings in these mice and in the other 4 strains of Kras knock-in mice reported to date (6, 9, 25, 29, 40, 47).”
BackgroundMethodResultSelf-citationEngineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?
Beurlet, S., Chomienne, C., & Padua, R. A. (2012) · Haematologica · doi:10.3324/haematol.2012.069385 · Cited by 25
“expressing KRASG12D from its endogenous locus using an Mx1Cre system also develop a rapid and lethal MDS/MPN with leukocytosis, monocytosis, severe anemia and BM features of dyserythropoiesis resembling JMML and CMML.(35,36,111,112) Furthermore, mice expressing NRASG12D from its endogenous locus (the Mx1Cre LoxSTP-Lox…”
Jin, X., Qin, T., Zhao, M., Bailey, N. G., Liu, L., Yang, K. B., Ng, V., Higashimoto, T., Coolon, R., Ney, G. M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017400 · Cited by 23
Caraffini, V., Geiger, O., Rosenberger, A., Hatzl, S., Perfler, B., Berg, J. L., Lim, C. X., Strobl, H., Kashofer, K., Schauer, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.209650 · Cited by 23
Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?
Itzykson, R., Fenaux, P., & Solary, É. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.09.006 · Cited by 24
“Knock-in of Kras– and Nras–mutated allele in mice recapitulates a MDS/MPN phenotype [51,52], with increased granulocytes and monocytes, probably triggered by constitutive ERK and STAT5 signaling, and hypersensitivity to GM-CSF and IL-3 [53].”
Ryu, M., Liu, Y., Zhong, X., Du, J., Peterson, N., Kong, G., Li, H., Wang, J., Salamat, S. M., Chang, Q., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357772 · Cited by 24
Matsuda, K., Nakazawa, Y., Sakashita, K., Shiohara, M., Yamauchi, K., & Koike, K. (2007) · Haematologica · doi:10.3324/haematol.11503 · Cited by 21
“These results suggest that the LOH resulted from duplication of the mutated allele through mitotic recombination, rather than from deletion of the NRAS part of wildtype chromosome 1p. Braun et al.8 reported that somatic activation of a latent KRASG12D allele rapidly induces a fatal myeloproliferative disorder in mice.”
Future of Early Detection of Lung Cancer: The Role of Mouse Models
Shaw, A. T., Kirsch, D. G., & Jacks, T. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-9005 · Cited by 21
Self-citationHe, S., Jing, C., & Look, A. T. (2017) · Methods in cell biology · doi:10.1016/bs.mcb.2016.11.013 · Cited by 23
“The oncogenic KRAS G12D mutant is sufficient to induce fully penetrant MPN in mice (Braun et al., 2004; Chan et al., 2004).”
BackgroundFlotho, C., Kratz, C. P., & Niemeyer, C. M. (2007) · Haematologica · doi:10.3324/haematol.11280 · Cited by 20
Pharmacogenetics of Alkylator-Associated Acute Myeloid Leukemia
Knoche, E., McLeod, H. L., & Graubert, T. A. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.5.719 · Cited by 19
Intracellular signaling by the erythropoietin receptor
Lodish, H. F., Ghaffari, S., Socolovsky, M., Tong, W., & Zhang, J. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8698-6_10 · Cited by 20
“Rather, this hyperactivates these EPO-dependent signaling pathways [85], which explains previous observations that hematopoietic progenitors expressing oncogenic K-ras from its endogenous locus display hypersensitivity to cytokine stimulation in various colony assays [86, 87 ].”
BackgroundRal Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras
Omidvar, N., Pearn, L., Burnett, A. K., & Darley, R. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.10.3966-3975.2006 · Cited by 22
“monocytic differentiation (10, 21), as well as to oppose the”
BackgroundJAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
Maslah, N., Kaci, N., Roux, B., Alexe, G., Marie, R., Pasquer, H., Verger, E., Oliveira, R. D. D., Culeux, C., Mlayah, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60884-1 · Cited by 18
Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia
Kropp, E. M., & Li, Q. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.04.001 · Cited by 20
Genua, C. D., Norfo, R., Rodríguez-Meira, A., Wen, W. X., Drissen, R., Booth, C. A. G., Povinelli, B. J., Repapi, E., Gray, N., Carrelha, J., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205351 · Cited by 19
“Finally, the Kras;Mx1-Cremouse model develops a fatal myeloproliferative neoplasm (MPN); however, these mice do not develop AML.(18,19) Collectively, these studies provide evidence that RAS mutations are secondary events in AML development and are not present within pre-leukemic HSC.”
BackgroundPLC-γ and PI3K Link Cytokines to ERK Activation in Hematopoietic Cells with Normal and OncogenicKras
Díaz-Flores, E., Goldschmidt, H. L., Depeille, P., Ng, V., Akutagawa, J., Krisman, K., Crone, M., Burgess, M. R., Williams, O., Houseman, B. T., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004125 · Cited by 23
“…PI3K stimulate ERK activation in hematopoietic cells from wild-type and Mx1-Cre, Kras G12D mice Compared to those of wild-type mice, the bone marrows of Mx1-Cre, Kras G12D mice contain a preponderance of myeloid cells with a corresponding loss of erythroid and lymphoid cell populations ( 10 , 11 ).”
InfluentialSelf-citationWild-type Kras expands and exhausts hematopoietic stem cells
Sasine, J. P., Himburg, H. A., Termini, C. M., Roos, M. M., Tran, E., Zhao, L., Kan, J., Li, M., Zhang, Y., de Barros, S. C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98197 · Cited by 18
Oncogenic K-Ras suppresses global miRNA function
Shui, B., Beyett, T. S., Chen, Z., Li, X., Rocca, G. L., Gazlay, W., Eck, M. J., Lau, K. S., Ventura, A., & Haigis, K. M. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.008 · Cited by 19
Forte, D., Barone, M., Morsiani, C., Simonetti, G., Fabbri, F., Bruno, S., Bandini, E., Sollazzo, D., Collura, S., Deregibus, M. C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01776-8 · Cited by 18
Merchant, S. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.09.002 · Cited by 19
Liu, Y. L., Yan, Y., Webster, C., Shao, L., Lensing, S., Ni, H., Feng, W., Colorado, N. C., Pathak, R., Xiang, Z., et al. (2016) · Blood · doi:10.1182/blood-2015-05-646216 · Cited by 17
Sachs, Z., Been, R. A., DeCoursin, K. J., Nguyen, H. T., Hassan, N. A. M., Noble-Orcutt, K. E., Eckfeldt, C. E., Pomeroy, E. J., Díaz-Flores, E., Geurts, J. L., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136002 · Cited by 18
Self-citationControversies of and Unique Issues in Hematopoietic Cell Transplantation for Infant Leukemia
Hunger, S. P., Loh, M. L., Baker, K. S., & Schultz, K. R. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.10.015 · Cited by 16
Sjogren, A.-K. M., Andersson, K., Khan, O. M., Olofsson, F. J., Karlsson, C., & Bergö, M. O. (2010) · Leukemia · doi:10.1038/leu.2010.242 · Cited by 16
“Injection of double-stranded RNA (pI-pC) into KM mice switches on the expression of oncogenic K-RAS (K-RAG12D) in hematopoietic cells and results in a progressive and lethal myeloproliferative disease (MPD) with myeloid leukocytosis, tissue infiltration, hepatosplenomegaly and hypersensitivity of hematopoietic cells t…”
BackgroundKRAS insertion mutations are oncogenic and exhibit distinct functional properties
White, Y. N., Bagchi, A., Ziffle, J. V., Sheth, A. I., Bollag, G. E., Zhang, C., Carias, H., Dickens, D. S., Loh, M. L., Shannon, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10647 · Cited by 16
Self-citationGenetic Analyses of the Role of RCE1 in RAS Membrane Association and Transformation
Bergö, M. O., Wahlstrom, A. M., Fong, L. G., & Young, S. G. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)38026-9 · Cited by 16
RAS Pathway Mutations in Juvenile Myelomonocytic Leukemia
Emanuel, P. D. (2008) · Acta Haematologica · doi:10.1159/000140632 · Cited by 16
“An analogous approach has expressed Cre off of the interferon-inducible Mx1 promoter. These conditional knock-out approaches have also confirmed that inactivation of Nf1 leads to the development of myeloproliferative features.The above described Mx1-Cre technology has also been applied to conditionally express oncogen…”
Tarnawsky, S. P., Chan, R. J., & Yöder, M. C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94031 · Cited by 16
“The Mx1Cre KrasG12D mouse was the first conditional animal model of JMML and continues to be studied extensively (12, 13).”
BackgroundDuctal activation of oncogenic KRAS alone induces sarcomatoid phenotype
Fu, Y., Cruz‐Monserrate, Z., Lin, H. H., Chung, Y., Ji, B., Lin, S.-M., Vonderfecht, S. L., Logsdon, C. D., Li, C., & Ann, D. K. (2015) · Scientific Reports · doi:10.1038/srep13347 · Cited by 13
“Rabbit anti-elastase I polyclonal antibody was from Life Span BioSciences, Inc. Biotin rat anti-mouse CD45 (53078), rat anti-mouse Ly-6G and Ly-6C (Gr-1) (550291) were from BD Biosciences and anti-mouse F4/80 (14-4801) was from eBioscience.”
MethodInfluential
Metadata
- Authors
- Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M.
- Affiliations
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- Departments of Pediatrics and Laboratory Medicine and Comprehensive Cancer Center, University of California, San Francisco, CA 94143; Abramson Center for Cancer Research, University of Pennsylvania, Philadelphia, PA 19104; Section of Hematology/Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL 60637; and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
- Corresponding author
- Shannon, Kevin M.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-12-29
- Volume
- 101
- Issue
- 2
- Pages
- 597-602
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC327193
- OpenAlex
- W2017349699
- Cited by
- 299
- References
- 53
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 10 · 2023: 3 · 2022: 5 · 2021: 12 · 2020: 7 · 2019: 12 · 2018: 9 · 2017: 8 · 2016: 13 · 2015: 8 · 2014: 24 · 2013: 16 · 2012: 17
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Frank A. Campini Foundation
- National Institutes of Health
- National Cancer Institute (CA 84221, R01CA072614, U01CA084221, U01CA084306, R37CA072614, CA84306, CA72614)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007636, T32 DK-07636)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- oncogenic KRAS, KRAS G12D, RAS mutations, myeloproliferative neoplasms, myeloid leukemia, hematopoietic cells, Ras-GTP, hyperproliferation, leukemogenesis, mouse model
- MeSH terms
- Animals, Bone Marrow Cells, Flow Cytometry, Karyotyping, Myeloproliferative Disorders, Genes, ras, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.